Illuminating the role of type I IFNs in colitis.

Abstract	Recently, type I interferons IFN-alpha and IFN-beta (IFN-alpha/beta) have been evaluated in pilot clinical trials for the treatment of active ulcerative colitis. However, the underlying mechanisms that may contribute to a potential therapeutic effect are incompletely understood. A new study in this issue demonstrates a protective role for IFN-alpha/beta, induced by activation of a Toll-like receptor 9-dependent pathway, in a rodent model of experimental colitis.
Authors	Stefan Wirtz, Markus F Neurath
Journal	The Journal of clinical investigation (J Clin Invest) Vol. 115 Issue 3 Pg. 586-8 (Mar 2005) ISSN: 0021-9738 [Print] United States
PMID	15765141 (Publication Type: Comment, Journal Article)
Chemical References	Interferon-alpha Interferon-beta
Topics	Animals Clinical Trials as Topic Colitis, Ulcerative (immunology, therapy) Humans Interferon-alpha (immunology) Interferon-beta (immunology) Intestines (cytology, immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!